Trials / Unknown
UnknownNCT03896854
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Pilot Study of the Efficacy and Safety of CD19 Targeted Chimeric Antigen Receptor Engineered T Cell in the Treatment of Relapsed or Refractory CD19 Positive Acute Myeloid Leukemia (AML)
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · Industry
- Sex
- All
- Age
- 6 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19 positive relapsed or refractory acute myeloid leukemia.
Detailed description
The patients will receive infusion of CART cells targeting CD19 to confirm the safety and efficacy of CD19 CART Cells in relapsed or refractory acute myeloid leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CART-19 | CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19 cells/kg). |
Timeline
- Start date
- 2017-10-18
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
- First posted
- 2019-04-01
- Last updated
- 2023-11-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03896854. Inclusion in this directory is not an endorsement.